Elizabeth Amanda Lippner, MD
Allergy & Immunology · Chicago
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Lippner’s office at (312) 227-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A135609 · Current
Licensed to practise in California · since 2015 · expires 2027-04-30 · Loyola University of Chicago Stritch School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036151019Licensed Physician And Surgeon · since 2019 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Allergy and Immunology - Allergy and Immunology
- American Board of Pediatrics - Pediatrics
Medicaid work
$13,481 in 2024
Medicaid paid $13,481 for 164 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| OFF/OP CNSLTJ NEW/EST MOD 40 | 47 | $6,030 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 64 | $3,844 |
| Return visit (30+ min) | 53 | $3,607 |
| 2024 | 164 | 3 | 20 | $13,481 |
| 2023 | 124 | 3 | 16 | $9,848 |
| 2022 | 495 | 6 | 24 | $48,767 |
| 2021 | 560 | 3 | 27 | $51,945 |
| 2020 | 150 | 4 | 18 | $11,465 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 74 | $5,018 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 25 | $3,367 |
| Return visit (30+ min) | 25 | $1,463 |
2022
| OFF/OP CNSLTJ NEW/EST MOD 40 | 135 | $21,102 |
| Long return visit (40+ min) | 157 | $14,867 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 80 | $4,994 |
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 78 | $4,642 |
| Return visit (30+ min) | 30 | $1,624 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 15 | $1,539 |
2021
| OFF/OP CNSLTJ NEW/EST MOD 40 | 199 | $31,242 |
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 246 | $11,841 |
| Long return visit (40+ min) | 115 | $8,862 |
2020
| OFF/OP CNSLTJ NEW/EST MOD 40 | 51 | $7,303 |
| Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests | 57 | $2,194 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 13 | $1,368 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 29 | $600 |
Money from drug and device companies
$324 in 2025
| 2025 | 6 | 7 | None | $324 |
| 2024 | 3 | 3 | None | $134 |
| 2023 | 2 | 7 | None | $1,098 |
| 2021 | 1 | 1 | None | $22 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Blueprint Medicines | Ayvakit | $114 | 1 payment
|
| ALK-Abello | None | $55 | 1 payment
|
| ARS Pharmaceuticals Operations | Neffy | $52 | 2 payments
|
| Pharming Healthcare | Ruconest | $52 | 1 payment
|
| CSL Behring | Hizentra | $27 | 1 payment
|
| Amgen | Actimmune | $24 | 1 payment
|
See all 7 published payments
| CSL Behring | Meals · 2025-12-09 | Hizentra | $27 |
| ARS Pharmaceuticals Operations | Meals · 2025-12-02 | Neffy | $29 |
| Amgen | Meals · 2025-07-09 | Actimmune | $24 |
| Pharming Healthcare | Meals · 2025-04-15 | Ruconest | $52 |
| ALK-Abello | Meals · 2025-03-01 | None | $55 |
| Blueprint Medicines | Meals · 2025-02-28 | Ayvakit | $114 |
| ARS Pharmaceuticals Operations | Meals · 2025-01-06 | Neffy | $23 |
See earlier years (2024, 2023, 2021)
2024: $134
| Amgen | Actimmune | $65 | 1 payment
|
| CSL Behring | Hizentra | $36 | 1 payment
|
| Grifols USA | Xembify | $33 | 1 payment
|
2023: $1,098
| Novartis Pharmaceuticals | None | $1,063 | 6 payments
|
| Regeneron Pharmaceuticals | Dupixent | $35 | 1 payment
|
2021: $22
| Grifols USA | Xembify | $22 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2023 | Their institution | $106,427 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis · 2023 | Their institution | $48,950 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2024 | Their institution | $48,275 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2023 | Their institution | $39,293 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2024 | Their institution | $30,170 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis · 2025 | Their institution | $27,035 |
| Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2022 | Their institution | $11,500 |
| Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis · 2024 | Their institution | $11,500 |
| Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2025 | Their institution | $4,601 |
Professional record
- NPI
- 1295179497
- Licence
- CA A135609, IL 036.151019California A135609: Current · expires 2027-04-30Illinois 036151019: Active
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207K00000X (207K00000X); Pediatrics (208000000X); Student in a training program (390200000X)
- Mailing address
- 225 E Chicago Ave, Chicago, IL, 60611
- NPI first listed
- 2013-04-18
- NPI last updated
- 2020-01-31
- NPI record certified
- 2020-01-31
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 757 Westwood Plz, Los Angeles, CA, 90095 · 269 Campus Drive Ccsr Building, Stanford, CA, 94305